Stephanie Slevin

Stephanie Slevin is a Senior Cell Biologist at Exscientia since March 2021, with prior experience as a Postdoctoral Researcher at the University of Oxford from March 2016 to March 2021. At Oxford, Slevin investigated checkpoint blockade-mediated autoimmune colitis as a research fellow for Bristol-Myers Squibb and explored the role of LAG-3 in Inflammatory Bowel Disease through a collaborative project with GlaxoSmithKline. Slevin completed a PhD in Clinical and Translational Medicine at Molecular Medicine Ireland from September 2011 to September 2015, focusing on the effects of Infliximab on Peripheral Blood Mononuclear Cells in patients with Inflammatory Bowel Disease. Additionally, Slevin gained experience in disease state analysis at Boston Scientific during a placement in R&D in 2012. Academic qualifications include a Doctor of Philosophy in Immunology and a Master of Science in Regenerative Medicine from the University of Galway, as well as a Bachelor of Science in Physiology from University College Cork.